1,304 reports of this reaction
4.0% of all LAPATINIB reports
#4 most reported adverse reaction
FATIGUE is the #4 most commonly reported adverse reaction for LAPATINIB, manufactured by Novartis Pharmaceuticals Corporation. There are 1,304 FDA adverse event reports linking LAPATINIB to FATIGUE. This represents approximately 4.0% of all 32,865 adverse event reports for this drug.
Patients taking LAPATINIB who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among LAPATINIB users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for LAPATINIB:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 1,304 FDA reports for LAPATINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 4.0% of all adverse event reports for LAPATINIB, making it a notable side effect.
If you experience fatigue while taking LAPATINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.